Join us for a virtual KOL event featuring Jonathan Barratt, PhD, FRCP (University of Leicester) who will discuss the disease burden and pathogenesis of IgA nephropathy (IgAN), as well as atacicept’s clinical data to-date.

Atacicept is a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to IgAN and certain other autoimmune diseases. In addition, the Vera Therapeutics leadership team will provide an overview of the Ph2b ORIGIN study of atacicept in IgAN and the Company’s pipeline.

A live Q&A session will follow the formal presentations.